• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>History and Technology >'Patenting in the public interest:' administration of insulin patents by the University of Toronto
【24h】

'Patenting in the public interest:' administration of insulin patents by the University of Toronto

机译：多伦多大学“为公共利益申请专利”对胰岛素专利的管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Whereas the norms of the academic world and medical ethics prohibited academics and doctors from applying for patents on medical inventions, the University of Toronto decided in 1922 to file a patent application on the discovery of insulin, covering both the therapeutic substance and the isolation and purification processes developed by the inventors. The University extended its patent to 25 countries in North America, Europe, Latin America, Australia, India and Japan. An Insulin Committee was set up to 'administer the patents in the public interest'. Toronto University's intention was to use its industrial property rights in a particular way: to control the standards and quality of a potentially dangerous drug, and to prevent the emergence of a monopoly that might limit the drug's accessibility to patients. The administration of insulin patents 'in the public interest' was a highly controversial subject during the inter-war years. On the one hand there were those who advocated regulation of the quality of drugs via patents and, on the other hand, those who opposed the idea of the University of Toronto receiving royalties to finance its medical research.
机译：鉴于学术界的规范和医学伦理禁止学者和医生申请有关医疗发明的专利，多伦多大学于1922年决定就发现胰岛素提出专利申请，涉及治疗物质以及分离和纯化。发明人开发的方法。该大学将其专利扩展到了北美，欧洲，拉丁美洲，澳大利亚，印度和日本的25个国家。成立了一个胰岛素委员会来“出于公共利益管理专利”。多伦多大学的意图是以特定方式使用其工业产权：控制潜在危险药物的标准和质量，并防止出现可能限制该药物对患者使用的垄断。在两次世界大战期间，“出于公共利益”的胰岛素专利管理是一个备受争议的主题。一方面有人主张通过专利来监管药品质量，另一方面有人反对多伦多大学获得特许权使用费以资助其医学研究的想法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号